Published in J Natl Cancer Inst on September 28, 2010
Skin Health Online for Melanoma: Better Risk Assessment (SOMBRA) | NCT03130569
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
Germline melanocortin-1-receptor genotype is associated with severity of cutaneous phenotype in congenital melanocytic nevi: a role for MC1R in human fetal development. J Invest Dermatol (2012) 1.56
Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet (2013) 1.04
GPCRs and cancer. Acta Pharmacol Sin (2012) 1.02
Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study. Pigment Cell Melanoma Res (2012) 0.98
MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation. Pigment Cell Melanoma Res (2014) 0.97
Rare presentations of primary melanoma and special populations: a systematic review. Am J Clin Oncol (2014) 0.92
Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer. Oncotarget (2014) 0.84
Malignant melanoma and melanocortin 1 receptor. Biochemistry (Mosc) (2013) 0.81
Melanoma epidemiology, biology and prognosis. EJC Suppl (2013) 0.78
MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors. Pigment Cell Melanoma Res (2014) 0.77
A large French case-control study emphasizes the role of rare Mc1R variants in melanoma risk. Biomed Res Int (2014) 0.76
Rare Germline Copy Number Variations and Disease Susceptibility in Familial Melanoma. J Invest Dermatol (2016) 0.76
Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature? Cancer Biol Ther (2016) 0.75
Pigmentary Markers in Danes - Associations with Quantitative Skin Colour, Nevi Count, Familial Atypical Multiple-Mole, and Melanoma Syndrome. PLoS One (2016) 0.75
Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study. BMC Res Notes (2015) 0.75
Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma. Genet Med (2015) 0.75
Implementing an Internet-Delivered Skin Cancer Genetic Testing Intervention to Improve Sun Protection Behavior in a Diverse Population: Protocol for a Randomized Controlled Trial. JMIR Res Protoc (2017) 0.75
Genetic and functional evaluation of MITF as a candidate gene for cutaneous melanoma predisposition in pigs. Mamm Genome (2011) 0.75
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet (1998) 23.25
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 13.68
ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell (1998) 8.99
Genetic determinants of hair, eye and skin pigmentation in Europeans. Nat Genet (2007) 8.79
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33
Germline p16 mutations in familial melanoma. Nat Genet (1994) 5.59
Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet (2000) 4.74
A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet (2008) 4.57
Evaluation of candidate genes in case-control studies: a statistical method to account for related subjects. Am J Hum Genet (2001) 4.09
Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet (2009) 3.89
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet (1994) 3.05
Cyclic AMP a key messenger in the regulation of skin pigmentation. Pigment Cell Res (2000) 2.98
Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst (2002) 2.70
Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet (2009) 2.65
MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst (2005) 2.57
Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science (1995) 2.42
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40
MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer (2008) 2.37
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol (2001) 2.16
Human pigmentation genes: identification, structure and consequences of polymorphic variation. Gene (2001) 2.03
Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev (2005) 1.95
Melanocortin-1 receptor structure and functional regulation. Pigment Cell Res (2005) 1.94
Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst (1997) 1.91
The genetics of sun sensitivity in humans. Am J Hum Genet (2004) 1.84
Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res (2006) 1.80
Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum Mutat (2007) 1.72
The Queensland Study of Melanoma: environmental and genetic associations (Q-MEGA); study design, baseline characteristics, and repeatability of phenotype and sun exposure measures. Twin Res Hum Genet (2008) 1.71
MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet (2001) 1.67
alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Res (2005) 1.58
Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles. Hum Mol Genet (2007) 1.52
Does MC1R genotype convey information about melanoma risk beyond risk phenotypes? Cancer (2010) 1.34
Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst (2004) 1.25
Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet (2001) 1.23
Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol (2005) 1.22
Melanin content and MC1R function independently affect UVR-induced DNA damage in cultured human melanocytes. Pigment Cell Res (2006) 1.20
Melanocortin-1 receptor signaling markedly induces the expression of the NR4A nuclear receptor subgroup in melanocytic cells. J Biol Chem (2008) 1.16
Assessment of polymorphic variants in the melanocortin-1 receptor gene with cutaneous pigmentation using an evolutionary approach. Cancer Epidemiol Biomarkers Prev (2004) 1.15
Pharmacological characterization of loss of function mutations of the human melanocortin 1 receptor that are associated with red hair. J Invest Dermatol (2004) 1.13
CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer (1999) 1.11
MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. Eur J Cancer (2010) 1.10
Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet (2004) 1.10
Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev (2005) 1.03
Mutation testing in melanoma families: INK4A, CDK4 and INK4D. Br J Cancer (1999) 1.01
MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability. J Med Genet (2005) 1.00
Val92Met variant of the melanocyte stimulating hormone receptor gene. Nat Genet (1996) 0.97
Regulation of human melanocortin 1 receptor signaling and trafficking by Thr-308 and Ser-316 and its alteration in variant alleles associated with red hair and skin cancer. J Biol Chem (2006) 0.96
A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). Eur J Cancer (2008) 0.95
Anti-inflammatory and anti-invasive effects of alpha-melanocyte-stimulating hormone in human melanoma cells. Br J Cancer (2003) 0.94
Re: MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst (2006) 0.92
MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters. Pigment Cell Melanoma Res (2008) 0.92
CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families. Br J Dermatol (2005) 0.92
Novel MC1R variants in Ligurian melanoma patients and controls. Hum Mutat (2004) 0.88
Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries. Int J Cancer (2007) 0.88
Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanoma-prone families. Cancer Epidemiol Biomarkers Prev (2000) 0.85
Ocular melanoma is not associated with CDKN2A or MC1R variants--a population-based study. Melanoma Res (2003) 0.79
MC1R variant alleles and malignant melanoma risk in Israel. Eur J Cancer (2009) 0.78
Alpha-melanocyte stimulating hormone potentiates p16/CDKN2A expression in human skin after ultraviolet irradiation. Cancer Res (2002) 0.77
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (2000) 15.53
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med (1997) 13.96
Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet (2001) 11.06
Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1993) 11.01
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 9.06
Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell (1996) 7.86
A cancer family syndrome in twenty-four kindreds. Cancer Res (1988) 6.39
Construction of linkage maps with DNA markers for human chromosomes. Nature (1985) 6.38
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res (1995) 5.72
Germline p16 mutations in familial melanoma. Nat Genet (1994) 5.59
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J (2003) 5.53
Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet (1997) 5.34
Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst (1989) 5.28
Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science (1987) 5.11
U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol (2002) 4.92
Long-term sensitivity of soil carbon turnover to warming. Nature (2005) 4.89
Improved plasmid vectors with a thermoinducible expression and temperature-regulated runaway replication. Gene (1983) 4.87
Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet (2000) 4.74
Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control (2001) 4.74
Characterization of the imitation switch subfamily of ATP-dependent chromatin-remodeling factors in Saccharomyces cerevisiae. Genes Dev (1999) 4.25
Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res (1990) 4.22
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J (2003) 4.20
Re-evaluation of the linkage relationship between chromosome 11p loci and the gene for bipolar affective disorder in the Old Order Amish. Nature (1989) 4.18
Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med (1987) 4.12
[Malignant skin melanoma a difficult clinical diagnosis. The primary management is often insufficient]. Lakartidningen (1997) 3.97
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet (2002) 3.67
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med (1998) 3.60
Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53
CDKN2A mutations in multiple primary melanomas. N Engl J Med (1998) 3.52
Occupational therapy for independent-living older adults. A randomized controlled trial. JAMA (1997) 3.47
A clinical trial of active management of labor. N Engl J Med (1995) 3.34
A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol (1984) 3.21
Experimentally-derived haplotypes substantially increase the efficiency of linkage disequilibrium studies. Nat Genet (2001) 3.20
Cancer incidence in a population accidentally exposed to 2,3,7,8-tetrachlorodibenzo-para-dioxin. Epidemiology (1993) 3.11
Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med (1989) 3.03
Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal cancers. N Engl J Med (1988) 3.01
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet (1996) 2.96
Effect of pregnancy on prognosis for young women with breast cancer. Lancet (1994) 2.92
Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet (1998) 2.90
[Primary cutaneous leiomyosarcoma: 32 cases]. Ann Dermatol Venereol (1999) 2.83
Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr (1998) 2.82
Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell (2000) 2.77
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst (2001) 2.74
Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst (2001) 2.73
A model for restriction fragment length distributions. Am J Hum Genet (1983) 2.71
Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst (2002) 2.70
Left handedness is uncommon in breast cancer patients. Eur J Cancer (1991) 2.70
The genome of Desulfotalea psychrophila, a sulfate-reducing bacterium from permanently cold Arctic sediments. Environ Microbiol (2004) 2.66
Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA (1997) 2.65
Seismicity remotely triggered by the magnitude 7.3 landers, california, earthquake. Science (1993) 2.61
The information content of phase-known matings for ordering genetic loci. Genet Epidemiol (1985) 2.59
The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. J Cell Sci (1998) 2.58
Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med (1985) 2.54
A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS (1999) 2.54
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology (2012) 2.54
Progressive juvenile-onset punctate cataracts caused by mutation of the gammaD-crystallin gene. Proc Natl Acad Sci U S A (1999) 2.53
Protection against allergen-induced asthma by salmeterol. Lancet (1990) 2.51
Dog bites of the face: a 15 year review. Br J Plast Surg (1983) 2.51
Case-control study of whether subfertility in men is familial. BMJ (1994) 2.49
Diagnosis of equine monocytic ehrlichiosis (Potomac horse fever) by indirect immunofluorescence. J Am Vet Med Assoc (1986) 2.49
Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst (1993) 2.44
Effectiveness of interventions to enhance physician screening for breast cancer. J Fam Pract (1995) 2.43
Intra-abdominal hypertension and abdominal compartment syndrome in burn patients. J Trauma (2000) 2.42
Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet (1995) 2.42
High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst (2000) 2.41
The Misgav Ladach method for cesarean section: method description. Acta Obstet Gynecol Scand (1999) 2.39
Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. Arch Neurol (1998) 2.38
Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol (2001) 2.36
E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol (2000) 2.36
P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer (2000) 2.35
Dermoscopy of Bowen's disease. Br J Dermatol (2004) 2.34
Melanoma and tumor thickness: challenges of early diagnosis. Arch Dermatol (1999) 2.34
Inactivation of the protein phosphatase 2A regulatory subunit A results in morphological and transcriptional defects in Saccharomyces cerevisiae. Mol Cell Biol (1992) 2.33
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet (1997) 2.33
The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet (1998) 2.32
Characterization of the human beta-crystallin gene Hu beta A3/A1 reveals ancestral relationships among the beta gamma-crystallin superfamily. J Biol Chem (1986) 2.31
That confounded P-value. Epidemiology (1998) 2.26
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26
The Danish case-control study of cutaneous malignant melanoma. II. Importance of UV-light exposure. Int J Cancer (1988) 2.26
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis (2005) 2.25
Viral genome organizer: a system for analyzing complete viral genomes. Virus Res (2000) 2.24
The requirement for macrophages in the in vitro immune response. Cell Immunol (1971) 2.24
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol (1998) 2.24
Indicators of prognosis in node-negative breast cancer. N Engl J Med (1990) 2.23